EP0221025A1 — Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals

USPTO Abstract

Compounds of formula wherein Ra is a group -X-Z. Rb is R 2 , Rc is R 3 , Rd is R 4 and Y is a group Ra is R 1 , Rb is a group -X-Z, Rc is R 2 , Rd is R 3 and Y is O, S or a group R 1 , R 2 , R 3 , and R 4 independently are C 1-6 alkyl not containing an asymmetric carbon atom. C 3-7 cycloalkyl or a ring or in the case of R 3 and R 4 additionally hydrogen, or for R 3 when Y is 0 or S whereby R 17 is hydrogen or C 1-3 alkyl and R 18 and R 19 are independently hydrogen C 1-3 alkyl or phenyl; each R 5 is independently hydrogen. C 1-3 alkyl, n-butyl, i-butyl. t-butyl, C 1-3 alkoxy, n-butoxy, i-butoxy. trifluoromethyl, fluoro, chloro. bromo, phenyl, phenoxy or benzyloxy; each R 6 is independently hydrogen. C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl. fluoro, chloro, bromo. phenoxy or benzyloxy, and each R 7 is independently hydrogen, C 1-2 alkyl, C 1-2 alkoxy, fluoro or chloro. with the proviso that there may only be one each of trifluoromethyl, phenoxy or benzyloxy in each ring A present X is (CH 2 ) m or (CH 2 )qCH =CH-(CH 2 ) q , m is 0.1. 2 or 3 and both q's are 0 or one is 0 and the other is 1. wherein Rg is hydrogen or C 1-3 alkyl, in free acid form. or in the form of an ester or δ-lactone thereof or in salt form as appropriate, which compounds are indicated for use as pharmaceuticals in particular as hypolipoproteinemic and anti-atherosclerotic agents.